Share this on:
 E-mail
129
VIEWS
0
COMMENTS
 
SHARES
About this iReport
  • Not verified by CNN

  • Click to view NeonDrum's profile
    Posted April 3, 2014 by
    NeonDrum
    Location
    Cambridge, United Kingdom

    More from NeonDrum

    Global regulatory affairs specialist ELC Group appoints Senior Regulatory Expert

     
    Cambridge, UK, 3rd April 2014 – ELC Group, one of the fastest-growing providers of regulatory affairs, today announces the appointment of Jin-Hee Kang as Senior Regulatory Expert specialising in Biosimilars. Jin-Hee Kang will be leading on support for Biosimilars development, focusing on legislative changes surrounding market launch.

    A former Associate Senior Director for Central Research Institute RA/CO with Celltrion Pharmaceuticals, Inc., Jin-Hee Kang was previously one of the key leaders behind the first monoclonal antibody biosimilar registration within the EMEA region, supervising the marketing authorisation from the feasibility studies to full launch logistics in over 130 countries.

    She previously worked with Otsuka Pharmaceutical, Inc. as RA Manager for six years. Her facilitation of new drug approval and launch accomplished a 150 per cent growth in the Asia and Arab markets in just two years.

    Speaking about the appointment, ELC Group's Head of Market Intelligence & Business Development, Akhil Jain said: "We offer Jin-Hee the warmest welcome to ELC Group and are excited with this new appointment. Kang has proved herself an expert in regulatory affairs over large geographies and we are confident in the growth of ELC Group’s Biosimilars business area under her supervision."

    Jin-Hee commented: "I am thrilled to be joining ELC Group as a Senior Regulatory Expert. ELC Group is one of the fastest growing industry experts and I look forward to working with the team in ensuring exemplary service when taking our clients’ products to market.”

    Kang studied Oriental Language Chinese at Hankuk University of Foreign Studies, Korea and is an accomplished linguist.

    --- ends ---

    Note to editors:
    If you would be interested in scheduling a briefing with ELC Group, please contact Nicky Denovan at nicky[at]evokedset[dot]com.

    Press contacts:
    Akhil Jain
    ELC Group
    ajain [at] elc-group [dot] com
    Phone: +420 22 491 00 00
    Nicky Denovan
    EvokedSet PR
    nicky[at] evokedset [dot] com
    Phone: +44 (0)7747 017654

    About ELC Group:
    ELC GROUP is a full-service global provider of regulatory affairs consultancy. ELC GROUP delivers a complete service solution covering all aspects of Regulatory Affairs for medicinal products, medical devices, cosmetics, food supplements and foods for special medicinal purposes. ELC GROUP also provides specialist REACH regulatory services to the Chemical industry and Corporate Language solutions for Automotive, Chemical and Defense industries.
    ELC GROUP’s worldwide network of professionals spans all major Regulatory Affairs services across the key healthcare vertical markets of Pharmaceuticals, Biotech, Clinical, Consumer Healthcare, Medical Devices, Nutraceuticals and Veterinary. The team ranges from former FDA investigators to individuals with over 30 years of industry experience and broad capabilities, including in the areas of integrated advanced technologies, Regulatory Affairs consulting and commercialisation services.

    ELC GROUP works with equal success in partnership with large multi-nationals, small enterprises and start-ups, biotechs, CROs and device manufacturers.


    Distributed on behalf of EvokedSet Ltd by NeonDrum news distribution service (http://www.neondrum.com)

    What do you think of this story?

    Select one of the options below. Your feedback will help tell CNN producers what to do with this iReport. If you'd like, you can explain your choice in the comments below.
    Be and editor! Choose an option below:
      Awesome! Put this on TV! Almost! Needs work. This submission violates iReport's community guidelines.

    Comments

    Log in to comment

    iReport welcomes a lively discussion, so comments on iReports are not pre-screened before they post. See the iReport community guidelines for details about content that is not welcome on iReport.

    Add your Story Add your Story